Teva Pulls Bipolar Drug After Lackluster Trial Results

Teva has pulled the plug on developing a new indication for its sleep disorder drug Nuvigil to treat bipolar I disorder after poor efficacy results from a final Phase III trial. Top-line results from the study, revealed by the drugmaker Aug. 30, failed to show that Nuvigil (armodafinil) was more effective than a placebo as a treatment for the disorder.
Washington Drug Letter